Literature DB >> 33441098

Comparison of survival in elderly patients treated with uretero-cutaneostomy or ileal conduit after radical cystectomy.

Shang Huang1, Hanzhong Chen1, Teng Li1, Xiaoyong Pu1, Jiumin Liu1, Xuecheng Bi2.   

Abstract

BACKGROUND: In bladder cancer patients with age ≥ 80 years old, there have been controversies in performing uretero-cutaneostomy or ileal conduit as urinary diversion after radical cystectomy. Limited study evaluated overall survival (OS) and cancer-specific survival (CSS) between the two urinary diversions in elderly patients. This study is to compare OS and CSS between uretero-cutaneostomy and ileal conduit after radical cystectomy in bladder cancer patients with age ≥ 80 years old. PATIENTS AND METHODS: Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Bladder cancer patients diagnosed between 2004 and 2016 with age ≥ 80 years old who underwent radical cystectomy with either UC or IC were selected. After propensity score matching, Cox regression and Kaplan-Meier analysis were used to analyze the survival. We calculated statistical power for survival.
RESULTS: Of 1394 patients who met the inclusion criteria, 1093 underwent ileal conduit and 301 underwent uretero-cutaneostomy. After propensity score matching, 285 patients were included in each group. Multivariable Cox analysis showed urinary diversion was not a risk factor of OS and CSS (HR 1.044, [95% CI 0.867-1.257] and 1.012 [0.748-1.368], respectively). Both OS and CSS were not significantly different, with median survival of ileal conduit and uretero-cutaneostomy were 19 [16-24] months and 19 [15-26] months respectively. Additionally, We found OS had the following risk factors: tumor stage (distant vs regional vs localized, 5.332 [3.610-7.875] vs 1.730 [1.375-2.176] vs 1), node density (>0.2 vs ≤0.2 vs none, 1.410 [1.047-1.898] vs 0.941 [0.658-1.344] vs 1) and age (1.067 [1.032-1.103] for each year). While CSS had the following risk factors: tumor stage (distant vs regional vs localized, 4.035 [2.046-7.959] vs 2.476 [1.651-3.713] vs 1), node density (>0.2 vs ≤0.2 vs none, 2.501 [1.645-3.804] vs 1.062 [0.590-1.914] vs 1) and tumor size (greater than 3 cm vs less than 3 cm, 1.596 [1.057-2.412] vs 1). Our analysis obtained 0.707 power for overall survival.
CONCLUSION: Urinary diversion by uretero-cutaneostomy or by ileal conduit was not associated with overall and cancer-specific survival. It is reasonable to consider uretero-cutaneostomy as a regular procedure of urinary diversion in elderly bladder cancer patients after radical cystectomy to avoid associate complications.

Entities:  

Keywords:  80 and over; Aged; SEER program; Urinary bladder neoplasms; Urinary diversion

Mesh:

Year:  2021        PMID: 33441098      PMCID: PMC7807694          DOI: 10.1186/s12877-020-01861-9

Source DB:  PubMed          Journal:  BMC Geriatr        ISSN: 1471-2318            Impact factor:   3.921


  26 in total

1.  Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder.

Authors:  Roman Mayr; Mattias May; Thomas Martini; Michele Lodde; Evi Comploj; Armin Pycha; Jenny Strobel; Stefan Denzinger; Wolfgang Otto; Wolfgang Wieland; Maximilian Burger; Hans-Martin Fritsche
Journal:  Eur Urol       Date:  2012-04-12       Impact factor: 20.096

2.  Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions.

Authors:  Jakko A Nieuwenhuijzen; Remco R de Vries; Alex Bex; Henk G van der Poel; Wim Meinhardt; Ninja Antonini; Simon Horenblas
Journal:  Eur Urol       Date:  2007-09-18       Impact factor: 20.096

3.  Charlson comorbidity score is associated with readmission to the index operative hospital after radical cystectomy and correlates with 90-day mortality risk.

Authors:  Coleman McFerrin; Syed Johar Raza; Allison May; Facundo Davaro; Sameer Siddiqui; Zachary Hamilton
Journal:  Int Urol Nephrol       Date:  2019-07-25       Impact factor: 2.370

4.  The impact of co-morbid disease on cancer control and survival following radical cystectomy.

Authors:  David C Miller; David A Taub; Rodney L Dunn; James E Montie; John T Wei
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

5.  Comparison of the Perioperative and Postoperative Outcomes of Ileal Conduit and Cutaneous Ureterostomy: A Propensity Score-Matched Analysis.

Authors:  Kotaro Suzuki; Nobuyuki Hinata; Taka-Aki Inoue; Ichiro Nakamura; Yuzo Nakano; Masato Fujisawa
Journal:  Urol Int       Date:  2019-12-18       Impact factor: 2.089

6.  Perioperative Outcomes and Early Survival in Octogenarians Who Underwent Radical Cystectomy for Bladder Cancer.

Authors:  Fabio Zattoni; Vito Palumbo; Gianluca Giannarini; Alessandro Crestani; Afrovita Kungulli; Giacomo Novara; Filiberto Zattoni; Vincenzo Ficarra
Journal:  Urol Int       Date:  2017-12-07       Impact factor: 2.089

7.  Cutaneous ureterostomy with definitive ureteral stent as urinary diversion option in unfit patients after radical cystectomy.

Authors:  Lucas Nogueira; Rodolfo Borges dos Reis; Roberto Dias Machado; Marcos Tobias-Machado; Gustavo Carvalhal; Celso Freitas; Wesley Magnabosco; Conrado Leonel Menezes; Carlos Corradi; Leonardo Oliveira Reis; Adauto Cologna; Antonio Antunes Rodrigues Junior; Eliney Ferreira Faria
Journal:  Acta Cir Bras       Date:  2013       Impact factor: 1.388

8.  Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA.

Authors:  Jeffrey J Leow; Alexander P Cole; Thomas Seisen; Joaquim Bellmunt; Matthew Mossanen; Mani Menon; Mark A Preston; Toni K Choueiri; Adam S Kibel; Benjamin I Chung; Maxine Sun; Steven L Chang; Quoc-Dien Trinh
Journal:  Eur Urol       Date:  2017-08-10       Impact factor: 20.096

9.  High mortality rates after radical cystectomy: we must have acceptable protocols and consider the rationale of cutaneous ureterostomy for high-risk patients.

Authors:  Fernando Korkes; Juan Palou
Journal:  Int Braz J Urol       Date:  2019 Nov-Dec       Impact factor: 1.541

10.  Demographic and Survivorship Disparities in Non-muscle-invasive Bladder Cancer in the United States.

Authors:  Munseok Seo; James R Langabeer Ii
Journal:  J Prev Med Public Health       Date:  2018-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.